Charles River Laboratories International In Stock Upgraded (CRL)

NEW YORK ( TheStreet) -- Charles River Laboratories International In (NYSE: CRL) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated.

Highlights from the ratings report include:
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, CHARLES RIVER LABS INTL INC's return on equity exceeds that of both the industry average and the S&P 500.
  • CHARLES RIVER LABS INTL INC' earnings per share from the most recent quarter came in slightly below the year earlier quarter. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CHARLES RIVER LABS INTL INC turned its bottom line around by earning $2.23 versus -$5.81 in the prior year. This year, the market expects an improvement in earnings ($2.68 versus $2.23).
  • Compared to where it was 12 months ago, the stock is up, but it has so far lagged the appreciation in the S&P 500. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • 41.90% is the gross profit margin for CHARLES RIVER LABS INTL INC which we consider to be strong. Regardless of CRL's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, CRL's net profit margin of 10.70% compares favorably to the industry average.
  • CRL, with its decline in revenue, slightly underperformed the industry average of 5.1%. Since the same quarter one year prior, revenues slightly dropped by 1.2%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. The company has a P/E ratio of 16.8, below the average drugs industry P/E ratio of 17.2 and below the S&P 500 P/E ratio of 17.7. Charles River Laboratories International In has a market cap of $1.76 billion and is part of the health care sector and drugs industry. Shares are up 31.2% year to date as of the close of trading on Wednesday.

You can view the full Charles River Laboratories International In Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Advanced Micro Devices, Micron Technology, Charles River Labs: 'Mad Money' Lightning Round

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)

Parexel Is Discovering the Drugs of the Future

Analysts' Actions -- GE, Nordstrom, Coca-Cola, Eli Lilly and More

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

Trader's Daily Notebook: For a Decline, It Sure Was Smooth